Literature DB >> 36057460

A low level of health literacy is a predictor of corticophobia in atopic dermatitis.

Tiago Fernandes Gomes1, Katarina Kieselova2, Victoria Guiote2, Martinha Henrique2, Felicidade Santiago2.   

Abstract

BACKGROUND: Topical corticosteroids (TCS) are the mainstay of treatment in atopic dermatitis (AD) flares. The fears and worries concerning TCS are known as corticophobia. Corticophobia is common in patients with AD and can lead to suboptimal TCS application and treatment failure. Health literacy (HL) may influence corticophobia. TOPICOP© and HLS-EU-PT questionnaires have been developed to evaluate corticophobia and HL, respectively.
OBJECTIVE: Evaluate the relationship between corticophobia and the degree of HL in patients with AD.
METHODS: Prospective cross-sectional study with AD patients followed at a Dermatology Department, between September 2019 and February 2020. Patients, or their parents (if patients had ≤ 15 years), were invited to answer TOPICOP© questionnaire, HLS-EU-PT questionnaire, and a disease characterization and demographic questionnaire.
RESULTS: We included 61 patients (57.4% females, mean age 20 ± 13.8 years, mean disease duration of 12.5 ± 11.4 years). TOPICOP© mean score was 44.8 ± 20.0 (8.3 to 88.9) and HLS-EU-PT mean score was 30.5 ± 8.5 (1.1 to 47.9). TOPICOP© score was negatively correlated with HLS-EU-PT score (p = 0.002, r = -0.382,  r2 = 0.146). There was no statistical difference between TOPICOP© score and disease characteristics (disease severity, family history of AD or personal history of other atopic diseases). STUDY LIMITATIONS: Small and heterogenous cohort composed of patients and patients' parents.
CONCLUSION: The degree of corticophobia is similar to the values reported in other studies. HL had an inverse correlation with corticophobia. Lower HL was shown to be a predictor of higher corticophobia. The promotion of health literacy is essential for the correct use of TCS and good control of AD.
Copyright © 2022 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Atopic; Dermatitis; Health literacy; Steroids; Therapeutics

Mesh:

Substances:

Year:  2022        PMID: 36057460      PMCID: PMC9582876          DOI: 10.1016/j.abd.2021.11.007

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   2.113


  30 in total

Review 1.  Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate.

Authors:  U Blume-Peytavi; U Wahn
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-05       Impact factor: 6.166

Review 2.  Epidemiology of adult atopic dermatitis.

Authors:  Ryan Sacotte; Jonathan I Silverberg
Journal:  Clin Dermatol       Date:  2018-05-31       Impact factor: 3.541

Review 3.  Factors contributing to poor treatment outcomes in childhood atopic dermatitis.

Authors:  Anna Sokolova; Saxon D Smith
Journal:  Australas J Dermatol       Date:  2015-03-29       Impact factor: 2.875

4.  Risk factors for corticophobia in atopic dermatitis.

Authors:  H Dufresne; P Bataille; N Bellon; S Compain; E Deladrière; L Bekel; E Sbidian; C Bodemer; S Hadj-Rabia
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-22       Impact factor: 6.166

5.  A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease - strategies for optimizing treatment outcome.

Authors:  L Eicher; M Knop; N Aszodi; S Senner; L E French; A Wollenberg
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-11-14       Impact factor: 6.166

6.  Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study.

Authors:  Jonathan I Silverberg; Jon M Hanifin
Journal:  J Allergy Clin Immunol       Date:  2013-10-04       Impact factor: 10.793

7.  Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three.

Authors:  Joseph A Odhiambo; Hywel C Williams; Tadd O Clayton; Colin F Robertson; M Innes Asher
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

8.  Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population.

Authors:  Zelma C Chiesa Fuxench; Julie K Block; Mark Boguniewicz; John Boyle; Luz Fonacier; Joel M Gelfand; Mitchell H Grayson; David J Margolis; Lynda Mitchell; Jonathan I Silverberg; Lawrence Schwartz; Eric L Simpson; Peck Y Ong
Journal:  J Invest Dermatol       Date:  2018-10-30       Impact factor: 8.551

9.  Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey.

Authors:  Maya El Hachem; Francesco Gesualdo; Giampaolo Ricci; Andrea Diociaiuti; Loredana Giraldi; Orsola Ametrano; Corrado Occella; Anna Belloni Fortina; Mirella Milioto; Fabio Arcangeli; Oriana Simonetti; Simona Giancristoforo; Elisabetta Calamelli; Carlo Mazzatenta; Iria Neri
Journal:  Ital J Pediatr       Date:  2017-02-28       Impact factor: 2.638

Review 10.  Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.

Authors:  Elaine C Siegfried; Jennifer C Jaworski; Jennifer D Kaiser; Adelaide A Hebert
Journal:  BMC Pediatr       Date:  2016-06-07       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.